4.6 Letter

Targeting complement in severe coronavirus disease 2019 to address microthrombosis

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Dawei Wang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Editorial Material Cardiac & Cardiovascular Systems

Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?

Courtney M. Campbell et al.

CIRCULATION (2020)

Article Critical Care Medicine

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Zhe Xu et al.

LANCET RESPIRATORY MEDICINE (2020)

Editorial Material Cardiac & Cardiovascular Systems

COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal

Hasan K. Siddiqi et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)

Letter Medicine, General & Internal

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Yan Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medical Laboratory Technology

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Giuseppe Lippi et al.

CLINICA CHIMICA ACTA (2020)

Article Transplantation

Eculizumab in secondary atypical haemolytic uraemic syndrome

Teresa Cavero et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)

Review Immunology

The role of C5a in acute lung injury induced by highly pathogenic viral infections

Renxi Wang et al.

EMERGING MICROBES & INFECTIONS (2015)

Article Biochemistry & Molecular Biology

Generation of C5a in the absence of C3: a new complement activation pathway

Markus Huber-Lang et al.

NATURE MEDICINE (2006)

Article Pathology

Generation of C5a by phagocytic cells

M Huber-Lang et al.

AMERICAN JOURNAL OF PATHOLOGY (2002)